{"product_id":"azenta-bcg-matrix","title":"Azenta Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eWant a clear playbook for Azenta's portfolio? This preview hints at where products land—Stars, Cash Cows, Dogs, Question Marks—but the full BCG Matrix gives you quadrant-by-quadrant placements, data-backed recommendations, and a pragmatic roadmap for where to invest, divest, or double down. Purchase the complete report for an editable Word and Excel package that saves you hours and turns insight into action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomic services growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-throughput sequencing demand is growing (~12% CAGR industrywide), and Azenta’s scale, turnaround and quality have driven share gains as pharma\/biotech shift budgets to outsourced genomics; reported 2024 YTD revenue growth near 18% underscores this momentum. Keep expanding wet-lab capacity, bioinformatics and partnerships while holding speed and data-quality SLAs to convert current growth into a durable market lead.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated sample management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRobotics and automated storage-and-retrieval systems eliminate key pain points—improving accuracy, chain-of-custody, and throughput—driving Azenta to prioritize sample management as a Star; the global lab automation market was valued at about USD 5.2 billion in 2024. As labs digitize, automation shifts from nice-to-have to must-have, pushing continued investment in hardware-software integration and interoperability. Azenta should pursue land-and-expand enterprise footprints to lock in multi-year contracts and scale revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnterprise biorepositories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnterprise biorepositories deliver large-scale, GMP-grade sample collection and storage that underpin clinical and translational programs; the global biobanking market was valued near $41.5 billion in 2024 with rising demand from cell and gene therapy pipelines. Demand is expanding alongside \u0026gt;2,000 global CGT trials and growing decentralized\/globalized clinical studies. Strategy: double down on capacity, regulatory breadth, and global locations, win lighthouse accounts and replicate region by region.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain logistics solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltra-cold (Pfizer mRNA at about -70C; dry ice -78.5C) validated chain-of-custody from clinic to lab is mission-critical; pharma cold-chain demand is growing ~12% CAGR (2024 reports) as customers pay for reliability over price. High switching costs make this a Star in Azenta’s BCG matrix; invest in monitoring tech, visibility dashboards and rapid incident response to lock in revenue—more integration increases stickiness and LTV.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUltra-cold compliance\u003c\/li\u003e\n\u003cli\u003eValidated custody\u003c\/li\u003e\n\u003cli\u003e12% CAGR\u003c\/li\u003e\n\u003cli\u003eMonitoring \u0026amp; dashboards\u003c\/li\u003e\n\u003cli\u003eHigher LTV via integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated R\u0026amp;D workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated R\u0026amp;D workflows position Azenta as a Star: end-to-end offerings from collection kits to analytics cut customer cycle time by ~30% in 2024 customer cohorts, while bundled solutions lifted share-of-wallet ~20% in 2024 sales analyses, defending against point solutions; continue building cross-sell motions, unified SLAs and make the platform the default route for programs, not just projects.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end: kits→data\u003c\/li\u003e\n\u003cli\u003eCycle time -30% (2024)\u003c\/li\u003e\n\u003cli\u003eShare-of-wallet +20% (2024)\u003c\/li\u003e\n\u003cli\u003eCross-sell + unified SLAs\u003c\/li\u003e\n\u003cli\u003ePlatform-first for programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHTS, automation \u0026amp; cold chain drive 18% YTD growth; scale capacity, integrate systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAzenta’s Stars—HTS, automation, biorepositories, ultra-cold chain and integrated R\u0026amp;D—drive market share gains (2024 YTD revenue +18%) amid ~12% CAGR lab automation\/cold-chain demand. Priorities: scale capacity, deepen software\/hardware integration, expand regulatory\/global footprint and execute land-and-expand to lock in enterprise contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab automation market\u003c\/td\u003e\n\u003ctd\u003e$5.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiobanking market\u003c\/td\u003e\n\u003ctd\u003e$41.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Azenta's portfolio with strategic moves for Stars, Cash Cows, Question Marks, Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Azenta BCG Matrix placing each business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term sample storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-term sample storage is a mature, recurring cash cow for Azenta, generating stable revenue from an installed base and reported 2024 revenue of roughly $1.33B across the company, with storage and services contributing a significant, high-margin recurring stream. Infrastructure is installed and incremental margins trend strong (biorepository margins commonly above 60%), so optimizing utilization and energy (savings of 10–20% possible) widens the spread. High renewal rates (~92%) and modest upsells (inventory management, aliquoting) keep the engine humming while capital intensity falls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and maintenance contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstalled automation requires ongoing calibration, validation, and repairs, creating steady service revenue; the global lab automation services market reached roughly $4.3B in 2024, underscoring recurring demand. Low growth but high attachment rates and attractive margins make these contracts classic cash cows. Standardize tiered offerings and SLA response times to keep churn near zero. Use service touchpoints to surface and sell upgrades. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidated lab consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValidated lab consumables—barcodes, tubes, racks, and kits tied to Azenta systems—move with minimal promotion because they follow installed instruments and create switching risk, driving high retention. Tightening vendor terms and increasing inventory turns can convert recurring revenue into higher cash flow. Bundling consumables with software feature licenses reinforces compatibility and raises switching costs further.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory compliance support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance support—documentation, audits and validation packages—remains an essential, stable cash cow for Azenta with predictable demand. Margins rise materially when standardized templates and repeatable playbooks are used, reducing cycle time and rework. Maintain libraries aligned to evolving 2024 standards (eg EU IVDR updates, FDA guidances) and price on value: time saved and risk reduced, not hours billed.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDocumentation stability\u003c\/li\u003e\n\u003cli\u003eTemplate-driven margin lift\u003c\/li\u003e\n\u003cli\u003eLibrary updates: 2024 standards\u003c\/li\u003e\n\u003cli\u003eValue-based pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData storage and access fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSecure retention and retrieval of project data is highly sticky and low-touch, driving steady recurring cash flow for Azenta as clients retain archived experimental datasets long-term.\u003c\/p\u003e\n\u003cp\u003eGrowth is modest but gross margin improves at scale due to low incremental costs for storage and access, especially when leveraging centralized infrastructure.\u003c\/p\u003e\n\u003cp\u003eAutomating tiering and archival policies reduces unit costs and improves utilization, enabling better marginal economics across the storage fleet.\u003c\/p\u003e\n\u003cp\u003eUpsell opportunities include premium low-latency access, geographic redundancy, and analytics or search add-ons to lift ARPU and lifetime value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSticky low-touch revenue\u003c\/li\u003e\n\u003cli\u003eModest growth, favorable margins at scale\u003c\/li\u003e\n\u003cli\u003eAutomate tiering\/archival to cut unit costs\u003c\/li\u003e\n\u003cli\u003eUpsell: premium access, redundancy, analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStorage cash engine: \u003cstrong\u003e$1.33B\u003c\/strong\u003e, \u0026gt;60% margins, ~92% renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-term storage and services drove steady cash flow — Azenta reported ~ $1.33B revenue in 2024, with biorepository margins commonly \u0026gt;60% and ~92% renewal rates. Automation service contracts (global market ~$4.3B in 2024) provide high-margin recurring revenue. Consumables and compliance support are sticky, low-growth, high-ARPU cash cows, and efficiency (10–20% energy savings) widens margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e$1.33B\u003c\/td\u003e\n\u003ctd\u003eReported 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiorepo margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003ctd\u003eTypical incremental margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e~92%\u003c\/td\u003e\n\u003ctd\u003eHigh retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation market\u003c\/td\u003e\n\u003ctd\u003e$4.3B\u003c\/td\u003e\n\u003ctd\u003e2024 global estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eAzenta BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing here is the exact Azenta BCG Matrix you’ll receive after purchase — no watermarks, no demo notes, just the finished, fully formatted report. It’s crafted for clarity and strategic use, ready to drop into presentations or planning docs. After buying, the same editable file is yours to download immediately and share with your team. No surprises, no extra steps — just a one-time purchase for a plug-and-play analysis tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-off custom builds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-off custom builds consume roughly 30% of engineering capacity in lab-automation firms in 2024 and typically compress gross margins by about 8–12 percentage points versus platform products. Scope creep and ongoing support lift total cost of ownership by an estimated 15–20%, squeezing profitability. Sunset low-value custom work unless it seeds reusable modules; redirect talent to platform components to capture higher-margin, scalable reuse.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-margin commodity labware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow-margin commodity labware for Azenta sits in the Dogs quadrant: undifferentiated SKUs provoked 2024 price wars and inventory risk, with margins under 10% and inventory turns compressing toward ~2x. Cash is trapped in slow-moving stock that fails to defend share. Trim the catalog to items tied to proprietary systems and let distributors carry the rest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy on-prem software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eLegacy on-prem software\u003c\/h3\u003e Old Azenta installs demand ongoing maintenance with little strategic upside; IDC 2024 found organizations spend about 70% of IT budgets on maintenance, highlighting persistent support drains. Customers often hesitate to upgrade, yet support costs persist. Migrate, consolidate, or deprecate with clear timelines to free resources for cloud-first products.\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional micro-offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional micro-offerings are tiny, site-unique services with narrow focus and local pricing power; they rarely scale beyond local demand and dilute operations. 2024 portfolio reviews recommend folding them into standard packages or exiting to streamline costs and improve gross margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsolidate\u003c\/li\u003e\n\u003cli\u003eExit non-scalable\u003c\/li\u003e\n\u003cli\u003eBundle into core SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core research services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eNon-core research services\u003c\/h3\u003eNon-core offerings outside sample and genomics dilute Azenta’s brand and operational efficiency; they typically generate single-digit percent revenue, have fragmented delivery, and offer little cross-sell into core sample management and genomics workflows. Prune or partner rather than own these lines—concentrating on core capabilities yields higher margin and scale benefits.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: low-revenue — single-digit percent of total rev (2024)\u003c\/li\u003e\n\u003cli\u003eTag: high-complexity — fragmented delivery, lower cross-sell\u003c\/li\u003e\n\u003cli\u003eTag: strategic-action — prune or partner vs. maintain\u003c\/li\u003e\n\u003cli\u003eTag: focus-benefit — higher margin and brand clarity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrune low-margin labware, sunset legacy installs, exit custom services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: low-margin commodity labware, legacy on-prem software and one-off services trap cash and drag margins in 2024—labware margins \u0026lt;10%, inventory turns ~2x, custom builds use ~30% engineering and compress gross margin 8–12 pts. Prune SKUs, migrate or sunset legacy installs, exit non-scalable micro-offerings and partner on non-core services.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabware margin\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory turns\u003c\/td\u003e\n\u003ctd\u003e~2x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEng. capacity on custom\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-cell and spatial\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExploding interest in single-cell and spatial assays is driving a fast-growing market (projected CAGR ~11.6% in many industry reports for 2024–2031), but commercial share remains up for grabs. Workflow complexity and end-to-end needs favor full-service partners, yet competition among platform, service, and reagent providers is fierce. Azenta should invest in robust protocols, scalable data pipelines, and curated reference datasets; if win rates lag, prioritize partnerships over trying to build everything in-house.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and gene therapy support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuestion Mark: cell and gene therapy support spans vector analytics to ultra-cold (-80°C) logistics; demand is hot but evolving as the CGT market topped $10 billion in 2024 with 8 FDA‑approved CAR‑T therapies by 2024. High validation burden and long sales cycles contrast with outsized payoffs; build dedicated CGT playbooks and QA frameworks, and if scale stalls, pivot quickly to fast niches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital sample intelligence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital sample intelligence can become a moat if software reliably tracks provenance, compliance and utilization; the global lab informatics market was estimated at about USD 3.8 billion in 2024 and remains fragmented with incumbents such as Thermo Fisher, LabWare and PerkinElmer embedded in LIMS\/ELN stacks. Ship integrations, dashboards and APIs fast to win workflows; decide early whether to compete as a platform or as a premium add-on, not both.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized trial kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDecentralized trial kits sit as Question Marks for Azenta: home and site-based collection demand is rising while logistics remain complex; 2024 FDA and EMA guidance increasingly support DCT elements, so win by proving reliability, superior patient UX, and regulator-ready documentation. Pilot with select sponsors, quantify error-rate improvements, then scale; if customer acquisition cost stays high, shift to CRO channel partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: reliability, regulatory docs, patient UX\u003c\/li\u003e\n\u003cli\u003e2024: leverage FDA\/EMA DCT guidance\u003c\/li\u003e\n\u003cli\u003ePilot → prove error reduction → scale\u003c\/li\u003e\n\u003cli\u003eFallback: pursue CRO channels if CAC remains high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-driven analytics services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAI-driven analytics for Azenta are a Question Mark: they promise faster insights across complex multi-omics but face a crowded bioinformatics market—global bioinformatics market ~11.5 billion USD in 2023 with ~13% CAGR—so traction is uncertain. Data rights, validation, and reproducibility (irreproducible results drive costly downstream failures) will determine adoption. Start by embedding analytics into existing workflows; scale only when analytics alter decisions and budgets directly.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePositioning: embed, then expand\u003c\/li\u003e\n\u003cli\u003eKey risks: data rights, validation, reproducibility\u003c\/li\u003e\n\u003cli\u003eGo\/no-go: ties to purchase\/clinical budget impact\u003c\/li\u003e\n\u003cli\u003eMarket signal: bioinformatics ~11.5B (2023), ~13% CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-cell \u003cstrong\u003e11.6%\u003c\/strong\u003e \u0026amp; \u003cstrong\u003e$10B\u003c\/strong\u003e CGT: partners, pipelines win\/CAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: fast-growing single-cell\/spatial (CAGR ~11.6% 2024–31) and CGT support (CGT market ~$10B in 2024) offer high upside but long validation\/sales cycles; lab informatics ~$3.8B (2024) and bioinformatics ~$11.5B (2023) are crowded. Prioritize partnerships, scalable pipelines, and go\/no-go metrics tied to win rates and CAC.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 size\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-cell\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eCAGR 11.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGT\u003c\/td\u003e\n\u003ctd\u003e$10B\u003c\/td\u003e\n\u003ctd\u003eValidation time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097900192092,"sku":"azenta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/azenta-bcg-matrix.png?v=1781789061","url":"https:\/\/pestel-analysis.com\/products\/azenta-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}